MedTrace Logo

Effects of Metformin in Heart Failure Patients

NCT02694289 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-11-23

No results posted yet for this study

Summary

Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety.

This is a single center, prospective trial. Subjects will be randomized to initiate metformin (starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on insulin products for management of their type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Metformin

Treatment/continuation of metformin therapy during admission

DRUG

Subcutaneous (sliding scale) Insulin

Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission

Sponsors & Collaborators

  • Maya Guglin

    lead OTHER

Principal Investigators

  • Maya Guglin, MD, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-09-10
Completion
2018-09-10

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02694289 on ClinicalTrials.gov